GlycoVaxyn AG

Historically, the method for producing glycoconjugate vaccines has been lengthy and complex with low yields, requiring two separate fermentation runs and numerous purification steps, as well as a tedious chemical conjugation step. In contrast, GlycoVaxyn AG's vaccine conjugates are produced in recombinant E. coli using a single fermentation run that includes the conjugation process, and subsequent downstream purifications.

Grabenstrasse 3

8952 Schlieren

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

More from Scrip

Syncona Looks To Go Private As Market Decline Deepens

 

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

Gilead’s Yeztugo Gets US Approval For Twice-Yearly PrEP

 

The first twice-yearly option for HIV prevention has been approved by the US Food and Drug Administration in an advance that “brings us closer than ever to ending the HIV epidemic,” said CEO Daniel O’Day.

ASCO: Pushing The Frontiers Of ADCs

 

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.